Background: Previous studies showed development of daptomycin non-susceptibility (DNS: MIC .4 mg/L) in Enterococcus faecalis infections. However, no studies have assessed the efficacy of the combination of daptomycin/ampicillin against E. faecalis strains developing DNS in the experimental endocarditis (EE) model.
Introduction
Enterococcal endocarditis is a growing concern for public health authorities and professionals involved in clinical microbiology and infectious diseases control, owing to an increasing prevalence and the rise of resistance to the main antibiotics used in its treatment. endocarditis (IE) due to enterococci. 2 High-level aminoglycoside resistance (HLAR) is spreading and is seen in .50% of the strains in large areas from different settings, particularly in Europe. 1 The combination of ampicillin/ceftriaxone had proven as efficacious as and safer than ampicillin/gentamicin against HLAR strains and it is likely to become the first choice in these cases. Currently, the treatment of choice according to international guidelines relies on the combination of a b-lactam (mainly ampicillin or penicillin) and an aminoglycoside or ampicillin/ceftriaxone, which is the first-line combination against HLAR strains.
3,4 However, further alternatives are lacking to treat HLAR and MDR E. faecalis strains and patients allergic to b-lactams.
Daptomycin is a lipopeptide antibiotic with rapid bactericidal activity against Gram-positive bacteria. Although it is not approved by the FDA for this indication, it is broadly used in the clinical setting for resistant enterococcal infections, including IE. 5 Data on susceptibility from a large recent study including 18 740 E. faecalis strains showed that daptomycin's in vitro activity against E. faecalis is excellent, with MIC 50/90 values of 1 and 2 mg/L, respectively, and 0.02% daptomycin non-susceptibility (DNS: MIC .4 mg/L). 6 Although most E. faecalis strains not exposed to daptomycin are thought to be susceptible to daptomycin (DS), its off-label use in monotherapy for severe infections has led to increasing reports of DNS strains and microbiological failure. 7 DNS has also been detected in patients not treated with daptomycin. 8 Daptomycin is FDA approved at doses of 4-6 mg/kg/day, but available data suggest that clinical outcomes and prevention of development of DNS are better with higher doses, namely 10-12 mg/kg/day. [9] [10] [11] [12] Another strategy to prevent the development of DNS is to combine daptomycin with other antibiotics. Recent clinical and laboratory data have shown that the combination of daptomycin and b-lactams (ampicillin, ceftobiprole, ceftaroline and ertapenem) is synergistic against vancomycin-resistant DNS enterococcal strains, likely due to an improved avidity of daptomycin for the enterococcal cell membrane caused by alterations of the surface charge induced by b-lactams. [13] [14] [15] [16] [17] [18] [19] Ceftaroline also showed the ability to restore daptomycin susceptibility. 20 Thus, it seems reliable that high inoculum infections such as IE need to be treated with high doses of daptomycin (.10 mg/kg/day) in combination with a b-lactam. However, data on the in vitro development of DNS among vancomycin-susceptible E. faecalis (VSE) IE strains are scanty and the efficacy of daptomycin plus b-lactams against DNS and DS E. faecalis has not been evaluated so far in the animal IE model.
Using our collection of E. faecalis strains from patients with IE, we aimed to assess the prevalence of DNS strains in vitro after subculture with inhibitory concentrations of daptomycin and to investigate in vivo whether the addition of ampicillin prevented the development of DNS. We also sought to determine the in vivo efficacy of high-dose daptomycin alone and in combination with ampicillin and to compare it with ampicillin/ceftriaxone against two different strains of HLAR E. faecalis: one strain developing DNS after in vitro exposure to daptomycin and one strain that did not.
Materials and methods

Microorganisms
We studied 82 VSE strains isolated from consecutive patients with IE diagnosed in our centre between 1995 and 2011. EFAE-188 and EFAE-324, both presenting HLAR, were selected for the in vivo studies. None of the patients had previously received daptomycin.
Antimicrobial agents
Daptomycin powder was supplied by Novartis International AG (Basel, Switzerland); ampicillin and ceftriaxone were purchased from Sigma-Aldrich. The drugs were prepared according to the manufacturers' recommendations.
Susceptibility testing
The MIC and MBC of daptomycin, ampicillin and ceftriaxone (Enterococcus spp. are intrinsically resistant to cephalosporins) were determined by the microdilution method using CAMHB according to current CLSI recommendations. 21 MIC/MBC of daptomycin and ampicillin were also tested with a higher inoculum (10 8 cfu/mL) than the recommended one of 10 6 cfu/mL to check the inoculum effect. All isolates were stored at -80 C in skimmed milk prior to testing. For daptomycin, broth was supplemented with Ca 2! to 50 mg/L according to the manufacturer's recommendations. E. faecalis ATCC 29212 was used as the control strain. Resistance to aminoglycosides was tested using the Etest method following the manufacturer's recommendations (bioMérieux). High-level resistance to gentamicin was defined as a gentamicin MIC !512 mg/L, high-level resistance to streptomycin as an MIC !1024 mg/L and HLAR as both gentamicin MIC !512 mg/L and streptomycin MIC !1024 mg/L.
Daptomycin resistance screening methodology
All strains were subcultured in the presence of daptomycin at 1 and 2 mg/L (being equivalent to two to eight times the MIC, depending on the strain) on Mueller-Hinton agar plates (Oxoid) supplemented with 50 mg/L Ca 2! . The final inoculum was 4-8 % 10 5 cfu/mL. Plates were incubated for up to 48 h. Streptococcus mitis-351 was used as a positive quality control strain. 22 In plates with positive growth in the presence of daptomycin, cfu were harvested and retested by the Etest method to check increased daptomycin MICs. Following the CLSI recommendations, strains with daptomycin MIC .4 mg/L were considered DNS. 21 Resistance screening test with daptomycin at 2 mg/L proved to be more consistent than with daptomycin at 1 mg/L. Thus, the former was selected as the final checkpoint.
Synergy studies
Time-kill methodology was used to test the activity of ampicillin/ceftriaxone and daptomycin/ampicillin according to previously described criteria. 23, 24 Series of flasks containing fresh Mueller-Hinton broth (supplemented with Ca 2! to a level of 50 mg/L) were inoculated with a standard inoculum (10 6 cfu/mL) and a high inoculum (10 8 cfu/mL) of bacteria from an overnight culture and further incubated at 36 C with aeration. When the strains were tested with the standard inoculum, antibiotics were used alone and in combination at final concentrations equal to the MIC or 0.5% MIC for the organisms for each drug. For ceftriaxone, a fixed concentration of 64 mg/L was chosen. Viability counts were performed at 0, 4 and 24 h. Drug carryover was addressed by dilution. Synergy was defined as a 2 log 10 cfu/mL decrease between the test tube with the combination and the test tube with the most active agent alone after 24 h. The number of surviving organisms in the presence of the combination had to be 2 log 10 cfu/mL below the starting inoculum. At least one of the drugs had to be present in a concentration that did not significantly affect the growth curve of the test organism when used alone. Bactericidal activity was defined as at least a 3 log 10 reduction in cfu/mL at 24 h in comparison with the initial inoculum. All experiments were done in duplicate and triplicate in case of discordant results.
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Study animals
Female, New Zealand White rabbits (body weight, 2.5 kg) provided by San Bernardo farm (Pamplona, Spain) were used. Housing took place in the animal facilities of the Technologics and Scientifics Center (CCiT) from the University of Barcelona, which is equipped with HEPA filtering in an automatic air exchange system, as well as a circadian light cycle. They were nourished ad libitum.
Ethics
The Committee of Animal Ethics of the University of Barcelona approved all animal experimentation in this study.
Human pharmacokinetic (PK) simulation studies
Antibiotics were administered by using a computer-controlled infusion pump system designed to reproduce human serum PK in rabbits after an intravenous (iv) infusion. As described before, animal drug doses were chosen to simulate the PK profiles of daptomycin (10 mg/kg of body weight iv every 24 h), ampicillin (2 g/4 h) and ceftriaxone (2 g/12 h) in humans. Ceftriaxone PK studies have been previously performed and already reported. 25 Daptomycin concentrations were determined by a validated HPLC assay to support the data previously reported by our group, using the microbiological bioassay method. 26 For ampicillin, to test the animal PK parameters, a single dose of 30 mg/kg ampicillin iv was administered to four healthy rabbits. To determine the serum concentrations, 1 mL of blood was collected through a catheter placed in the carotid artery at different times (0, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2 and 2.5 h for ampicillin). Samples were centrifuged at 12 000 rpm for 20 min, serum was removed and antibiotic concentrations were measured. The ampicillin concentrations in serum were assayed using the disc-plate bioassay method, described elsewhere with Micrococcus luteus (ATCC 9341) as the bioassay microorganism and Antibiotic medium no. 5 agar as the growth medium. 24 The sensitivity of the ampicillin bioassay was 0.2 mg/L.
Daptomycin HPLC analysis
The method was validated and applied for drug quantification in rabbit serum at the Laboratory of Pharmacology and Toxicology Unit. Serum daptomycin concentrations were determined using a validated HPLC method adapted to a UV detector. The method was linear for daptomycin concentrations ranging from 10 to 800 mg/L. Analytical results of calibration standards in terms of percentage precision and percentage accuracy fulfilled all of the acceptance criteria. 27 The overall precision and accuracy measurements, expressed as percentage coefficient of variation and as percentage mean deviation, were 10%, in terms of absolute values. The limit of quantification was 10 mg/L daptomycin. Briefly, serum samples, calibrators or quality controls (100 lL) were mixed with acetonitrile (100 lL) and centrifuged at 12 000 rpm for 5 min. An aliquot of 25 lL of the supernatant was injected. Chromatographic separation was performed on a Waters Alliance 2695 system using a Waters Symmetry C18 analytical column (4.6 mm id % 75 mm, 3.5 lm particle size). The mobile phase consisted of a mixture of 0.2 M sodium phosphate buffer (pH 5.5) and acetonitrile [70/30 (v/v)]. The pump flow rate was 1 mL/min, products were monitored at a UV wavelength of 223 nm and the total run time was 5 min.
Experimental endocarditis model
The experimental aortic valve IE model was induced according to the method described by Garrison and Freedman. 28 Briefly, a catheter was inserted through the right carotid artery into the left ventricle of anaesthetized rabbits; two separated catheters were used for antibiotic administration and were placed into the inferior vena cava through the jugular vein. The external portion of each jugular catheter was connected to a swivel and then to a computer-controlled infusion pump as previously described. 29 The infusion pump delivered 2 mL/h of 0.9% saline solution until the beginning of antimicrobial administration. Twenty-four hours later, each animal was inoculated via the marginal ear vein with either the EFAE-188 or the EFAE-324 strain (1 mL of 1 % 10 8 cfu/mL; dose equal to ID 90 ). Before initiation of the antimicrobial therapy, 1 mL of blood was obtained to confirm bacteraemia. Antibiotic treatments were started and animals were treated for 72 h using a computer-controlled pump. After completion of the treatment, an additional six half-lives were allowed to elapse before the animals were sacrificed (anaesthetized and euthanized by using an iv bolus of pentobarbital). Aortic valve vegetations were obtained, weighed, homogenized in 2 mL of saline solution and quantitative and qualitative cultures were performed as already reported. 29 Homogenate samples were quantitatively cultured on plates containing Columbia agar with 5% sheep blood (bioMérieux). The remaining homogenate (1.7 mL) was qualitatively cultured in tryptic soy broth for a week. The recovered bacteria were retested to confirm their daptomycin MICs.
Treatment groups
The infected rabbits were separated into the different treatment arms simulating human PK. Monotherapy was 10 mg/kg daptomycin iv every 24 h. Combined therapy was 10 mg/kg/day daptomycin iv plus 2 g/4 h ampicillin iv and 2 g/4 h ampicillin iv plus 2 g/12 h ceftriaxone iv. Each group included 10 animals.
Analysis of endocardial vegetations
The cfu counts recovered from vegetations were expressed as the number of log 10 cfu/g of vegetation (log 10 cfu/g veg). The result was assigned a value of 2 log 10 cfu/g veg if there was no growth on the quantitative plates but there was growth in the qualitative culture and from the homogenate cultures for a week. The result was assigned a value of 0 and the vegetation was considered sterile if there was no growth from the initial quantitative and qualitative culture and from the homogenates cultured for a week.
All the isolates recovered from vegetations were stored. To detect in vivo emerging resistance, daptomycin MICs were re-tested by the Etest and microdilution methods.
Statistical analysis
The results were expressed as the median and IQR of the number of log 10 cfu/g veg. The Mann-Whitney non-parametric test was used to compare the log 10 cfu tissue values among the different treatment groups. The Fisher exact test was used to compare the rate of sterilized vegetations and analyse whether there were differences between treatment groups.
Results
Susceptibility testing
The daptomycin MIC 50 /MIC 90 (range) and MBC 50 /MBC 90 (range) for the entire E. faecalis collection (n=82) were 1/2 mg/L (0. Peric as et al.
Results of daptomycin screening test
The overall frequency of DNS among the screened strains was 33% (27 of 82). For these 27 strains, daptomycin MIC rose from 0. Table S1 (available as Supplementary data at JAC Online). From the 17 HLAR strains, 8 were selected to perform the in vitro synergy study: 5 strains that kept the susceptibility in the presence of daptomycin (DS strains: EFAE-71, EFAE-97, EFAE-324, EFAE-603 and EFAE-727) and 3 strains (DNS strains: EFAE-188, EFAE-645 and EFAE-728) that developed DNS in the same conditions (see Table S1 ). The MICs/MBCs of ampicillin and daptomycin with two different inocula for the eight E. faecalis strains are summarized in Table 1 .
In vitro time-kill experiments
Time-kill curves (TKCs) of double antibiotic combination results are summarized in Tables 2-5 . The results obtained from the DNS strains are displayed in Table 2 (inoculum equal to 10 6 cfu/ mL) and Table 3 (inoculum equal to 10 8 cfu/mL). Using the standard inoculum of 10 6 cfu/mL, daptomycin/ampicillin was synergistic in two of three strains, but did not reach a bactericidal effect in any case. For ampicillin/ceftriaxone, synergy was found in three of three strains and the bactericidal effect was detected only in one strain. When the higher inoculum was used, the synergistic activity of the daptomycin/ampicillin combination was missed in all cases (Table 3) , but the ampicillin/ceftriaxone combination retained the synergistic activity in two of three cases and the bactericidal activity was detected in two strains. Tables 4 and 5 summarize the results for the DS strains. For all the strains tested, daptomycin/ampicillin was synergistic but presented a bactericidal effect just in one case. For ampicillin/ceftriaxone, we found synergy in three of five strains but no bactericidal effect was detected in any case. When the higher inoculum was used, the synergistic activity of daptomycin/ampicillin was missed in all cases except one (Table 5) , whereas ampicillin/ceftriaxone had synergistic and bactericidal activity in two of five strains.
Among these eight strains, two presenting similar results (synergy) when tested against both daptomycin/ampicillin and ampicillin/ceftriaxone were selected for the in vivo study: EFAE-188 as the DNS strain and EFAE-324 as the DS strain ( Figures S1 and S2  respectively) . Standard inoculum is 10 6 cfu/mL; high inoculum is 10 8 cfu/mL. Results shown are the change in log 10 cfu/mL at the timepoint specified. 
AMP, ampicillin; CRO, ceftriaxone; DAP, daptomycin. a In vivo study DNS strain. b Results shown are the change in log 10 cfu/mL at the timepoint specified.
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Human PK simulation studies
The results of the human-like approach of ampicillin simulating the human dose of 2 g/4 h are shown in Table 6 and Figure S3 . HPLC analysis supported the previous data obtained with the bioassay method. The mean PK values for the tested antibiotics are shown in Table 6 . For each antibiotic, the achieved mean maximum concentration (C max ) and trough concentration (C min ) were: 150/18 mg/L daptomycin for a 10 mg/kg/24 h simulated dose, 96/7 mg/L ampicillin for a 2 g/4 h simulated dose and 250/45 mg/L ceftriaxone for a 2 g/12 h dose.
Treatment of established endocarditis
The activity of the drugs in monotherapy or combined therapies is summarized in Table 7 . All control rabbits had infected aortic valve vegetations, with a median bacterial titre of 8.5-9 log 10 cfu/g veg for both strains. Sterile vegetations were not found in any case. Comparisons between treated groups revealed that after 72 h of treatment, high-dose daptomycin monotherapy (10 mg/kg/24 h) was not able to significantly reduce the density of microorganisms in the vegetations. Concerning the combined therapy arms, ampicillin/ceftriaxone therapy was synergistic against both strains, with higher activity against the DS strain compared with the DNS strain that showed a tendency to statistical significance (P " 0.052). Compared with daptomycin alone, ampicillin/ceftriaxone was significantly more active against both strains (P,0.001 for the DS strain and P " 0.02 for the DNS strain). Daptomycin/ampicillin was synergistic and bactericidal against the DS strain, while it did not reach a bactericidal effect against the DNS strain (P " 0.002). Against the DS strain, daptomycin/ampicillin was significantly more active than daptomycin monotherapy (P,0.001) and as effective as ampicillin/ceftriaxone (P " 0.67); the latter, though, reduced the median number of cfu in the vegetations of treated animals to a greater extent. However, no statistical differences between the two treatment groups were found for the DNS strain (P " 0.07 for the comparison with daptomycin alone and P " 0.2 compared with ampicillin/ceftriaxone).
No cases of emerging DNS were detected during the treatment with daptomycin. All the isolates recovered from the Results shown are the change in log 10 cfu/mL at the timepoint specified. Results shown are the change in log 10 cfu/mL at the timepoint specified. 
Discussion
This study provides evidence indicating that the in vitro appearance of DNS is not an uncommon phenomenon among HLAR VSE strains. A third of the 82 E. faecalis strains screened developed DNS after subculture with daptomycin. This is of note because although its treatment is not so challenging as for VRE, VSE, with or without HLAR, it is the most common agent of enterococcal IE worldwide 1, 2 and daptomycin is increasingly used for its treatment. 1, 5, 12, 13, 19 The incidence of DNS in clinical strains of VSE exposed to suboptimal dosages of daptomycin and the relationship between the in vitro and in vivo findings of DNS is not well known, as studies performed so far did not include sufficient numbers of strains, 30, 31 provided only in vitro data 6 or focused on therapy without assessing the development of DNS. 13, 19 Entenza et al. 32 tested the ability to develop in vitro DNS in four strains of enterococci, two Enterococccus faecium and two E. faecalis (one VSE and one VRE). The only strain that did not show DNS after serial exposure to daptomycin was the VSE and the combination with ampicillin prevented the emergence of DNS in all four strains. 32 In vitro, daptomycin/ampicillin showed synergistic activity against both DS and DNS strains when the inoculum was low, but this effect dropped when higher inocula were used (for DS strains, overall synergy fell from 100% to 20% and for DNS strains, it fell from 66% to 0%). This loss of efficacy was not observed with ampicillin/ceftriaxone, which, consistently with previous studies, 33 showed good in vitro activity against HLAR E. faecalis both against low (75%) and high (50%) inocula regardless of daptomycin susceptibility and bactericidal activity was found in 50% of strains.
The in vitro/in vivo results were consistent for the selected DS strain (EFAE-324), for which both ampicillin/ceftriaxone and daptomycin/ampicillin showed synergy in the high inoculum TKCs and in the rabbit experimental model. Nevertheless, we cannot predict the results for the other DS strains that showed no synergy with high inoculum in the TKCs and were not assessed in vivo. As for the selected DNS strain (EFAE-188), its in vitro screening of DNS development frequently produced positive results but we found no emergence of daptomycin resistance in the subculture of vegetations from rabbits treated with daptomycin, either in monotherapy or combined with ampicillin. Meanwhile, in vivo activity of the daptomycin/ampicillin combination was only partially predicted by the TKC: the synergistic activity was lost in vitro against the selected DNS strain when using the high inoculum and this combination was significantly much less active when compared with the DS strain (EFAE-324) in the rabbit model of experimental endocarditis. Furthermore, it is reasonable to assume that daptomycin/ampicillin will not be active against the other two DNS strains, which were not tested in vivo due to the lack of synergy in the highinoculum TKC.
As far as we know, there are no available studies using the rabbit model to evaluate the efficacy of daptomycin against VSE. In other models, such as the rat model, the activity of daptomycin in vitro against DS E. faecalis remained virtually the same in vivo, alone 34, 35 and combined with agents other than ampicillin, namely fosfomycin. 36 Rice et al. 36 found in vitro synergy with the daptomycin/fosfomycin combination against HLAR VSE, but there were no differences in the efficacy between daptomycin monotherapy and combined with fosfomycin. These authors concluded that the in vitro bactericidal synergism between these two agents against strains of enterococci would not necessarily translate into greater therapeutic efficacy in clinical infections. Thus, although we cannot rely on other comparable studies to provide a robust explanation of this phenomenon, it seems that contradictions between in vitro and in vivo findings in E. faecalis combination treatment studies are not unusual. Moreover, we did not perform other structural, functional or genetic studies on the cell wall of isolates recovered from vegetations, such as searching for septae by electronic microscopy, changes in the cell wall phospholipids and typical mutations underlying DNS in enterococci, as previously described. 1, 30, 31 These limitations preclude any further hypothesis trying to explain these contradictory findings.
However, a key finding showing good correlation between in vitro data and in vivo results is that while the DNS strain did not respond to either daptomycin or daptomycin/ampicillin, good in vivo results with daptomycin/ampicillin were found against the DS strain. Notably, daptomycin alone was indifferent against this strain too. The practical consequences of this finding may be highly relevant: the performance of an Etest for daptomycin MIC in case of growth of an IE HLAR E. faecalis strain after subculture with inhibitory doses of daptomycin might be very helpful. In case the daptomycin MIC increases with respect to that of the initial blood isolate, daptomycin/ ampicillin should be avoided. This is a simple procedure that could be carried out in the first 24 h of treatment since the identification of E. faecalis in blood cultures and can be performed in all microbiology laboratories. Daptomycin/ampicillin could be included in the armamentarium depending on the initial Etest after subculture with daptomycin inhibitory concentrations in case of relapse after using another combination (basically, ampicillin/ceftriaxone), development of renal toxicity due to gentamicin (in cases without HLAR) or lack of synergy in in vitro studies with ampicillin/ceftriaxone. Daptomycin/ampicillin for E. faecalis endocarditis
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Concerning the results on the efficacy of the different regimens used in the experimental model, the main finding, besides the good activity of ampicillin/ceftriaxone against both selected strains and also the remarkable performance of daptomycin/ampicillin against the DS strain, is that daptomycin in monotherapy, despite being administered at 10 mg/kg/day, was inefficacious against both strains. This contradicts the results of previous experimental studies, using even smaller doses of daptomycin in vivo against E. faecalis 9,34,35 and the clinical intuition based on limited evidence that high doses of daptomycin are efficacious against VRE and VSE. 5, 11, 12 Since no DNS isolates were recovered from vegetations of infected rabbits and daptomycin in monotherapy was equally inefficacious against both strains, we do not think that the lack of efficacy observed is related to resistance phenomena, but rather that enterococci are highly tolerant to daptomycin, 37 as they are against other cell wall active agents, at least in the experimental field. 38 The addition of another cell wall agent, such as ampicillin, did not overcome this limitation. It did not confer either synergy or bactericidal activity against a high inoculum DNS strain. In addition, as initial MICs for the E. faecalis were not in the range of DNS and no DNS isolates were recovered from the vegetations of the daptomycin monotherapy arm, we cannot conclude that the addition of ampicillin inhibited the development of DNS. With regard to the good efficacy of daptomycin/ampicillin against the DS strain, we assume that the underlying mechanism is the enhanced binding of daptomycin to the cell membrane and the sensitization of E. faecalis to killing by ampicillin, as proven with ceftaroline. 19 There is evidence available that the combination of daptomycin with ampicillin or ceftaroline does also increase binding of daptomycin to the cell wall of DNS enterococci. 15 Further studies are needed to confirm that the combination of daptomycin/ampicillin is not efficacious against E. faecalis with in vitro ability to develop DNS and to elucidate the mechanisms that differentiate isolates with MICs in the DNS range for the first blood isolate from those with normal MICs that are prone to develop DNS when exposed to subtherapeutic concentrations of daptomycin.
This study has several limitations. First, only 8 of 82 strains from our cohort were studied through TKC methodology and only one strain developing DNS in vitro and one not developing DNS were tested in the experimental endocarditis model. Secondly, although clinically consistent, the choice of only HLAR strains limits the range of our conclusions. Thirdly, population analysis profile studies to detect E. faecalis daptomycin heteroresistant populations were not performed in all the strains, thus precluding the assessment of ampicillin efficacy in the prevention of DNS development. Fourth, we did not go more deeply in the in vitro and in vivo findings by also studying mutations in the systems controlling the cell membrane alterations underlying DNS, structural changes of the cell wall or changes in the membrane fatty acids. Lastly, we did not include an experimental arm assessing the efficacy of a regular dose of daptomycin (equal to 6 mg/kg/day) alone, ampicillin in monotherapy and both combined to compare them with their respective equivalents at high daptomycin dosages.
In conclusion, a third of the E. faecalis strains from IE episodes in our cohort presented the ability to develop DNS in vitro. This finding was associated with non-responsiveness in vivo to the daptomycin/ampicillin combination using an HLAR strain while its efficacy was equal to ampicillin/ceftriaxone against the selected DS strain. Thus, performing an Etest on the strains growing after daptomycin subculture with inhibitory concentrations may be a helpful tool to determine whether daptomycin/ampicillin is a good therapeutic option in E. faecalis IE.
